Azenta finalized documentation supporting the completed sale of B Medical, agreeing to a $35 million vendor loan to buyer Thelema at 6% interest with a three-month maturity. The loan is secured by a first-priority pledge over 100% of B Medical’s equity and may be subordinated or released upon refinancing and full repayment. A Deed of Amendment to the sale agreement designates the vendor loan as part of the $63 million purchase price, alongside $28 million paid at or before closing. These steps provide short-term buyer financing while enabling Azenta to close the transaction.
Agreement 1: Azenta Provides $35 Million Secured Vendor Loan at 6% to Support B Medical Sale
- Agreement type: Secured short-term vendor term loan
- Counterparty: Thelema
- Signed / Effective: Jul 01 2026 / Jul 01 2026
- Duration / Termination: 3 months
- Reason: Facilitate completion of B Medical sale
Agreement 2: Azenta Takes First-Priority Pledge of B Medical Shares to Secure $35 Million Vendor Loan
- Agreement type: First-priority share pledge over 100% of B Medical equity
- Counterparty: Thelema
- Signed / Effective: Jul 01 2026 / Jul 01 2026
- Duration / Termination: Until loan repaid
- Reason: Secure repayment of vendor loan
Agreement 3: Azenta Amends B Medical Sale Agreement; $35 Million Price Payable via Vendor Loan
- Agreement type: Deed of amendment to Sale and Purchase Agreement
- Counterparty: Thelema
- Signed / Effective: Jul 01 2026 / Jul 01 2026
- Duration / Termination: At will
- Reason: Reflect vendor loan and updated closing mechanics
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.